Immunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of "Buy" from Brokerages

Key Points

• Immunic, Inc. (NASDAQ:IMUX) received an average consensus rating of "Buy" from five brokerages, with an average 1-year target price of $7.00.
• Analysts from D. Boral Capital and HC Wainwright set target prices of $10.00, while Chardan Capital set a lower target price of $3.00 for the company.
• Institutional investors hold 51.82% of Immunic's stock, with significant increases in holdings reported by Jane Street Group and Millennium Management in recent quarters.

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has been assigned a consensus rating of "Buy" from the five brokerages that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $7.00.

Several equities analysts recently weighed in on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $10.00 target price on shares of Immunic in a research note on Thursday. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Immunic in a research note on Friday. Finally, Chardan Capital assumed coverage on shares of Immunic in a research note on Monday. They set a "buy" rating and a $3.00 target price for the company.

Immunic Price Performance

Shares of NASDAQ IMUX opened at $0.94 on Monday. The firm has a fifty day moving average price of $0.90 and a 200-day moving average price of $0.92. The stock has a market cap of $92.64 million, a PE ratio of -1.00 and a beta of 1.44. Immunic has a 1 year low of $0.56 and a 1 year high of $1.73.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). On average, research analysts expect that Immunic will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Immunic

Several institutional investors have recently bought and sold shares of IMUX. Jane Street Group LLC lifted its position in Immunic by 279.3% during the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock valued at $226,000 after purchasing an additional 152,726 shares during the last quarter. 683 Capital Management LLC lifted its holdings in shares of Immunic by 28.6% in the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock worth $981,000 after acquiring an additional 200,000 shares during the last quarter. Focus Partners Wealth lifted its holdings in shares of Immunic by 19.1% in the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company's stock worth $2,816,000 after acquiring an additional 415,104 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company's stock worth $580,000 after acquiring an additional 479,846 shares during the last quarter. Finally, Aberdeen Group plc bought a new stake in shares of Immunic in the 1st quarter worth about $1,155,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.